Bank of Montreal’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$265K Sell
12,138
-3,104
-20% -$64.6K ﹤0.01% 2846
2026
Q1
$356K Buy
+15,242
New +$331K ﹤0.01% 2563
2021
Q2
– Sell
-2,256
Closed -$52K – 4782
2021
Q1
$52K Sell
2,256
-3,705
-62% -$83.7K ﹤0.01% 3681
2020
Q4
$141K Buy
5,961
+2,913
+96% +$60.4K ﹤0.01% 3400
2020
Q3
$51K Sell
3,048
-914
-23% -$13.9K ﹤0.01% 3420
2020
Q2
$61K Buy
3,962
+2,074
+110% +$31.6K ﹤0.01% 3334
2020
Q1
$18K Sell
1,888
-2,789
-60% -$26.2K ﹤0.01% 3295
2019
Q4
$41K Buy
4,677
+792
+20% +$5.82K ﹤0.01% 3941
2019
Q3
$29K Buy
3,885
+61
+2% +$556 ﹤0.01% 3884
2019
Q2
$36K Buy
+3,824
New +$27.9K ﹤0.01% 3842
2019
Q1
– Sell
-189
Closed -$1K – 4703
2018
Q4
$1K Buy
189
+93
+97% +$510 ﹤0.01% 4558
2018
Q3
$1K Sell
96
-9
-9% -$64 ﹤0.01% 4595
2018
Q2
$1K Buy
+105
New +$1.03K ﹤0.01% 4585
2017
Q3
– Sell
-11,329
Closed -$158K – 4310
2017
Q2
$158K Buy
+11,329
New +$130K ﹤0.01% 2772

Other funds holding SNDX

Bank of Montreal's SNDX Position: Q2 2026 in Review

Bank of Montreal reduced its Syndax Pharmaceuticals (SNDX) stake by 20% in Q2 2026, selling an estimated $64.6K and leaving 12,138 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2846.

Bank of Montreal first reported a position in SNDX in Q2 2017 and has held it in 14 quarters since. The position peaked at $356K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Bank of Montreal held 12,138 shares of Syndax Pharmaceuticals worth $265K as of Q2 2026.
  • Bank of Montreal sold 3,104 Syndax Pharmaceuticals shares in Q2 2026, an estimated $64.6K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2846 holding.
  • Bank of Montreal first reported a position in Syndax Pharmaceuticals in Q2 2017 and has held it in 14 quarters since.
  • Bank of Montreal's Syndax Pharmaceuticals position peaked at $356K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.